Is Cancer a Single Disease or 200 Different Diseases?
In this article
Modern oncology's greatest discovery: cancer is not a single enemy but a vast family of diseases, each bearing a different genetic signature in every individual.
Why Is There No «Single Cancer»?
The misconception that cancer is one disease stems from an organ-centered approach. When we say «lung cancer», we actually mean dozens of subtypes that begin in the same organ but have entirely different genetic engines. Data from 2025 show that one patient's lung cancer may be biologically more similar to another patient's breast cancer if, for example, both carry a HER2 mutation.
Every tumor is shaped by specific mutations in the patient's own DNA. This makes each case as unique as a «snowflake».
In breast cancer alone, more than 15 major genetic subtypes and hundreds of rare variations have been identified as of 2026.
Three Dimensions of Complexity: Genetics, Epigenetics and the Microenvironment
Three fundamental layers underlie the description of cancer as 200+ diseases. The 2025-2026 oncology guidelines link treatment success to accurate analysis of these three layers:
1. Cell of Origin (Histology)
Traditionally, we classify cancers as arising from epithelial cells (carcinomas), connective tissue (sarcomas) or blood cells (leukemias). Even this basic classification rests on more than 200 different cell types. The mechanism by which each cell type becomes cancerous uses different signaling pathways.
2. Driver Mutations (The Genetic Engine)
In modern medicine, «What drives it?» has become more important than «Where did it start?». Mutations such as EGFR, ALK, KRAS and BRAF are the true identities determining cancer's behavior. In 2026 oncology practice, «agnostic treatments»—drugs directed only at the mutation, regardless of the organ—are the strongest evidence of this diversity.
2026 Genomic Mapping Data
AI analyses have revealed that even within a single tumor (intratumoral heterogeneity), there are 5 to 10 distinct cell populations with different genetic characteristics.
3. The Tumor Microenvironment (Ecosystem)
Cancer is not just the cancer cell. It forms an ecosystem with surrounding immune cells, blood vessels and signaling molecules. While some «diseases» hide from the immune system (cold tumors), others are at war with it (hot tumors). This interaction is one of the main factors dividing cancer into 200 different biological scenarios.
Cancer's «Diversity» Table: Why Are They Different?
| Feature | Type A (e.g., Luminal A Breast Cancer) | Type B (e.g., Triple-Negative) | Clinical Consequence |
|---|---|---|---|
| Growth Rate | Slow / Hormone-Sensitive | Very Fast / Aggressive | Different Follow-Up Protocol |
| Treatment Target | Estrogen Receptor | Chemotherapy / Immunotherapy | Entirely Different Drug Classes |
| Spread (Metastasis) | Usually Bone-Predominant | Brain- and Lung-Predominant | Different Screening Methods |
| Genetic Profile | Low Mutational Burden | High Genomic Instability | Personalized Dosing |
DROZDOGAN Academy Commentary
The word cancer is a very broad concept, just like «inflammation» or «infection». We used to tell patients, «You have stage 4 lung cancer». Today, we say, «Your disease is a specific oncological condition carrying a ROS1 translocation, with low PD-L1 expression and abundant fibroblasts in its microenvironment».
Although the fact that cancer comprises 200 different diseases may seem frightening, it is actually a great source of hope. The more specifically we define the enemy, the more precisely we can choose our weapon. As of 2026, the era of «one treatment fits all» has ended, and the era of «a strategy for every tumor» has begun. Healing lies in the details.
Scientific References and 2025-2026 Data Sources
- 1. Hanahan D. Hallmarks of Cancer: New Dimensions for 2025. Cancer Discovery 2025.
- 2. World Cancer Report 2026: Molecular Classification and Global Trends. IARC Scientific Publications.
- 3. AI-Driven Proteogenomics in Clinical Oncology: A 2026 Review. Nature Reviews Cancer.
- 4. Precision Medicine Initiative: Beyond Organ-Centric Therapy. The Lancet Oncology, January 2026.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.